-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
FWM-1
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/fwm-1.gif)
| Category | SARS-CoV |
| Description | FWM-1 is a potent SARS-COV-2 NSP13 helicase enzyme inhibitor with binding free energy equals -328.6 kcal/mol. FWM-1 effectively disrupts the binding of ATP to the SARS-COV2 helicase enzyme. |
Product Information
| Synonyms | FWM-1|NSP13 inhibitor 1|GLXC-25162|ZINC12599408|AKOS001016049|HY-144800|CS-0434621|5,5'-[(4-chlorophenyl)methylene]bis(2-mercapto-4,6-pyrimidinediol)|5,5'-((4-Chlorophenyl)methylene)bis(6-hydroxy-2-thioxo-2,3-dihydropyrimidin-4(1H)-one) |
| Molecular Weight | 410.86 |
| Molecular Formula | C15H11ClN4O4S2 |
| Canonical SMILES | C1=CC(=CC=C1C(C2=C(NC(=S)NC2=O)O)C3=C(NC(=S)NC3=O)O)Cl |
| Purity | ≥98% |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Complexity | 707 |
| Exact Mass | 409.9910249 |
| Target | SARS-CoV |
| XLogP3-AA | 1.1 |
